Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.
November 07, 2024 16:05 ET | Source: CytoSorbents

CytoSorbents Reports Third Quarter 2024 Financial and Operational Results

PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
November 04, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification

CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
October 22, 2024 07:00 ET | Source: CytoSorbents

FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review

FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
October 01, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
May 02, 2024 07:00 ET | Source: CytoSorbents

CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe

CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
December 28, 2023 07:00 ET | Source: CytoSorbents

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
February 21, 2023 01:00 ET | Source: Xeltis

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices New investors DaVita Venture Group and Invest-NL join syndicate of international...
February 17, 2023 12:00 ET | Source: Corline Biomedical AB

Corline Biomedical AB: Tecknar samarbetsavtal för CHS™-coatning av bypassgraft med ambition att starta kliniska studier 2023

Corline har tecknat ett utvecklings- och samarbetsavtal med en europeisk leverantör av kärlgrafter för bypassoperationer som används vid kirurgi för patienter med hjärtinfarkt. Avtalet reglerar...